Parathyroid hormone (1-34) (human): Mechanistic Precision for Bone and Kidney Research

Executive Summary: Parathyroid hormone (1-34) (human) is a bioactive 34-amino-acid peptide fragment that acts as a potent parathyroid hormone 1 receptor agonist and calcium homeostasis regulator (APExBIO). The peptide exhibits an IC50 of 0.22 nM for cAMP stimulation in human kidney 293 cells, supporting robust intracellular signaling (Huang et al., 2025). It has demonstrated dose- and time-dependent increases in bone mass in vivo in male Fisher 344 rats. The product's high solubility in DMSO and water, along with >97.8% purity, ensures experimental reproducibility. Parathyroid hormone (1-34) (human) is optimized for advanced bone metabolism, osteoporosis, and next-generation kidney assembloid research.

Biological Rationale

Parathyroid hormone (1-34) (human), with the sequence H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH, represents the active N-terminal fragment of the full-length parathyroid hormone secreted by chief cells of the parathyroid glands (APExBIO). This peptide fragment retains full biological activity for receptor activation and downstream signaling. PTH (1-34) is essential for calcium and phosphate homeostasis in vertebrates. It acts by binding to the parathyroid hormone 1 receptor (PTH1R) and, with lower affinity, to the parathyroid hormone 2 receptor (PTH2R), modulating bone turnover and renal and intestinal calcium handling (see Mechanistic Benchmark article). This precise action differentiates it from full-length PTH and synthetic analogs, making it a gold standard for physiological and pathological studies of bone and kidney function. Recent advances in kidney assembloid and organoid modeling have further increased demand for well-characterized PTH (1-34) reagents in translational pipelines (Huang et al., 2025).

Mechanism of Action of Parathyroid hormone (1-34) (human)

Upon administration, PTH (1-34) binds to PTH1R, a G protein-coupled receptor (GPCR) present in bone, kidney, and other tissues. Receptor activation triggers two primary intracellular signaling cascades:

• cAMP Pathway: Gs protein activation leads to adenylyl cyclase stimulation, increasing intracellular cAMP levels. In HEK293 cells transfected with PTH1R, the peptide shows an IC50 of 0.22 nM for cAMP generation at 37°C, pH 7.4 (APExBIO).
• Inositol Phosphate Synthesis: Gq protein coupling leads to phospholipase C activation and inositol phosphate production, modulating calcium release from intracellular stores (see Advanced Insights article).

Downstream, these pathways result in:

• Release of calcium from bone matrix via osteoclast activation.
• Increased renal tubular reabsorption of calcium and magnesium, primarily in distal tubules and thick ascending limb.
• Enhanced intestinal calcium absorption secondary to upregulation of 1,25-dihydroxyvitamin D synthesis.

The net effect is precise regulation of serum calcium and phosphate concentrations. The mechanistic profile of PTH (1-34) is distinct in its rapid-onset and receptor-specific action compared to full-length hormone or analogs (see Precision Disease Modeling article).

Evidence & Benchmarks

• PTH (1-34) stimulates cAMP production in human kidney 293 cells with an IC50 of 0.22 nM at 37°C, pH 7.4 (APExBIO).
• Solubility exceeds 399.3 mg/mL in DMSO and 19.88 mg/mL in water, enabling high-concentration stock solutions for in vitro and in vivo studies (APExBIO).
• Male Fisher 344 rats administered 10 or 40 μg/kg/day subcutaneously exhibit dose- and time-dependent increases in trabecular and cortical bone mass (Huang et al., 2025).
• Spatially patterned kidney assembloid models employ PTH (1-34) to recapitulate in vivo PTH/PTHrP receptor signaling and calcium handling, supporting high-fidelity disease modeling (Huang et al., 2025).
• Product purity exceeds 97.8%, verified by HPLC profile and mass spectrometry, minimizing batch-to-batch variability (APExBIO).

Applications, Limits & Misconceptions

Key Applications:

• Modeling calcium and phosphate homeostasis in vertebrate systems.
• Benchmarking bone formation and resorption in osteoporosis and bone metabolism research.
• Recapitulating PTH/PTHrP receptor signaling in kidney assembloid and organoid models (Huang et al., 2025).
• Evaluating cAMP and inositol phosphate signaling pathways in transfected cell systems.

This article extends previous overviews such as the Mechanistic Benchmark by providing updated benchmarks for kidney assembloid fidelity, and clarifies distinctions from the Precision Disease Modeling article by mapping workflow integration parameters.

Common Pitfalls or Misconceptions

• PTH (1-34) (human) is not suitable for diagnostic or clinical therapeutic use—research use only.
• The peptide does not fully recapitulate long-term effects of chronic PTH exposure seen with endogenous hormone.
• Solution stability is limited; avoid prolonged storage and use freshly prepared aliquots to prevent degradation (APExBIO).
• Improper solvent selection (e.g., ethanol) results in insolubility and loss of activity.
• Effects in non-mammalian systems or in vitro models lacking PTH1R expression are not guaranteed.

Workflow Integration & Parameters

For optimal results, dissolve Parathyroid hormone (1-34) (human) at ≥399.3 mg/mL in DMSO or ≥19.88 mg/mL in sterile water. Avoid ethanol as a solvent due to insolubility. Prepare working aliquots fresh prior to experimental use. Store the solid form desiccated at -20°C to preserve potency. For cell-based assays, titrate concentrations to match the IC50 for cAMP response in your system, starting from nanomolar ranges (APExBIO). In animal studies, follow validated dosing regimens (e.g., 10–40 μg/kg/day subcutaneously in rats), adjusting for species and endpoint. Incorporate appropriate vehicle and receptor-negative controls. For high-fidelity kidney assembloid models, verify PTH1R/PTH2R expression and link observed phenotypic effects to downstream cAMP or inositol phosphate pathway activation (Huang et al., 2025).

Conclusion & Outlook

Parathyroid hormone (1-34) (human) from APExBIO (A1129) is a rigorously characterized, high-purity peptide fragment optimized for research on bone metabolism, calcium homeostasis regulation, and next-generation kidney disease modeling. Its validated mechanism as a parathyroid hormone 1 receptor agonist, robust cAMP signaling, and compatibility with advanced assembloid platforms position it as a reference standard for reproducible, translationally relevant investigations. For deeper mechanistic context and emerging applications, see our comparative review in Advanced Insights, which integrates pathway analysis and regenerative medicine perspectives. Adoption of PTH (1-34) in high-fidelity models is expected to accelerate discovery in bone and kidney research and support advances in organoid-based disease modeling (Huang et al., 2025).